Clinical trials
Immunity clinical trials
Below are recruiting immunity clinical trials, each written for real people, not researchers. We’re tracking 975 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07366593Recruiting
Immune & respiratory health in Down syndrome kids with pneumonia
This study looks at how the immune system and breathing are affected in children with Down syndrome who have pneumonia. It aims to find patterns that could lead to better treatments.
CairoAges 1–6 - NCT07362199RecruitingPhase 2
New combo treatment for chronic ITP
This trial tests combining two antibodies (anti-CD38 and rituximab) for adults with chronic ITP who haven't been helped by steroids or other standard treatments. The goal is to see if this drug pair can raise platelet counts and reduce bleeding risk.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06829238RecruitingPhase 4
Metformin to boost immune function in people with a history of drug use
This study tests whether metformin, a common diabetes drug, can help restore immune system balance in people who have used injection drugs in the past. It includes both people living with HIV and those who are HIV-negative.
Birmingham, AlabamaAges 18–64 - NCT07341750Recruiting
Probiotic study for immune health in school-aged children
This trial tests whether a probiotic called Bacillus Coagulans SNZ 1969 can support the immune health of healthy children aged 6 to 12. Your child would take the probiotic or a placebo daily for a period while keeping their usual routine.
London, OntarioAges 6–12 - NCT06708429Recruiting
Lynch syndrome and gut immune system study
This study looks at how the immune system interacts with the gut lining in people with Lynch syndrome and those without. It may help us better understand how Lynch syndrome affects the body.
Monrovia, CaliforniaAges 18 years+ - NCT04518475RecruitingPhase 4
Eltrombopag with rituximab versus eltrombopag alone for ITP
This trial compares two treatment approaches for adults with primary immune thrombocytopenia (ITP), a condition where platelet counts are too low. It looks at whether adding rituximab to eltrombopag helps control ITP better and more safely.
TianjinAges 18–60 - NCT07297563RecruitingPhase 2
Anti-CD38 antibody vs rituximab for hard-to-treat ITP
This trial tests a new antibody drug (anti-CD38) compared to a standard drug (rituximab) for adults with ITP that hasn't responded well to steroids. The goal is to see if the new drug works better at raising platelet counts and reducing bleeding risk.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07297394Recruiting
How the immune system supports early pregnancy
This study looks at how the immune system helps the body accept a pregnancy. It involves blood samples from people who are pregnant or going through IVF/ICSI, or who have had a miscarriage.
BaselAges 18 years+ - NCT07294365RecruitingPhase 2
Study of DZD8586 for adults with chronic ITP
This study tests an investigational drug called DZD8586 for people with long-term ITP (low platelets) that hasn't improved with standard treatments. The goal is to see if it can safely raise platelet counts and reduce bleeding risk.
Jinan, ShandongAges 18 years+ - NCT06950697Recruiting
Blood clot risk prediction for lung cancer patients on immunotherapy
This study builds a tool to predict blood clot risk in lung cancer patients receiving immune checkpoint inhibitors. Researchers will use your data to develop a more personalized risk assessment, which may help prevent dangerous clots during treatment.
Zhengzhou, HenanAges 18 years+ - NCT07273708Recruiting
Immune cell study in liver cancer patients on immunotherapy
This study looks at how your immune cells respond to two specific immunotherapy-based treatments for advanced liver cancer. Researchers want to understand why some patients respond well and others do not, which could help improve future care.
Pavia, LombardyAges 18–90 - NCT07559331RecruitingPhase 3
Dexamethasone plus Orelabrutinib for newly diagnosed immune thrombocytopenia
This trial tests whether adding a drug called orelabrutinib to high-dose dexamethasone (a steroid) works better than dexamethasone alone for treating newly diagnosed immune thrombocytopenia (ITP)—a condition where your body destroys its own platelets, causing very low blood counts. The goal is to see if the combination helps raise your platelet count and prevents bleeding.
Jinan, ShandongAges 18–80 - NCT06544499RecruitingPhase 3
Efgartigimod for adults with chronic ITP
This study tests an investigational drug called efgartigimod, given through a vein, for adults with chronic immune thrombocytopenia (ITP) who have not responded well to other treatments. The goal is to see if it safely raises platelet counts and reduces bleeding risk.
Phoenix, ArizonaAges 18 years+ - NCT07268872Enrolling by invitation
How anesthesia drugs affect immune function in healthy adults
This trial studies how different anesthesia drugs affect the immune system in healthy young adults. It may help doctors choose safer anesthetics for future patients.
Henan, ZhengzhouAges 20–30 - NCT07249060Recruiting
Interferon levels in cancer and autoimmune disease patients
This study looks at a protein called interferon in the blood of people with cancer who are starting immunotherapy, and people with certain autoimmune diseases (such as lupus, Sjögren's syndrome, scleroderma, or inflammatory myopathy). The goal is to compare interferon patterns and better understand immune responses.
Pamplona, NavarreAges 18 years+ - NCT07233213RecruitingPhase 3
IVIG for chronic low platelet condition
This trial tests an intravenous immunoglobulin (IVIG) treatment for chronic immune thrombocytopenia (ITP), a condition where the immune system attacks platelets, causing low counts and bleeding risk. It aims to safely raise platelet levels using donated antibodies.
Ankara, AltındağAges 18–65 - NCT07234019RecruitingPhase 2
Rituximab plus anti-CD38 antibody for ITP
This trial tests whether adding an anti-CD38 antibody to the standard drug rituximab works better than rituximab alone for adults with long-term immune thrombocytopenia (ITP) who have already tried steroids without lasting success.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07221643Recruiting
Carotenoids, skin health and immune aging study
This study looks at how natural compounds in the skin called carotenoids relate to immune changes as we age. It compares younger and older healthy adults to understand aging better.
Redwood City, CaliforniaAges 18 years+ - NCT07206758RecruitingPhase 1
Study of SHR-2173 for immune thrombocytopenia (ITP)
This study tests a new medication called SHR-2173 for people with immune thrombocytopenia (ITP) whose platelet count is low and who have already tried steroids without success. The goal is to see if this drug can help raise platelet counts and reduce bleeding risk.
Wuhan, HubeiAges 18 years+ - NCT05354765Recruiting
Collect immune cells by lymphapheresis to study cancer response
This trial studies how changing your immune system (with earlier treatments) affects cancer by collecting immune cells from your blood using a process called lymphapheresis. It may help researchers find better ways to monitor immune-related responses and side effects.
ParisAges 18 years+ - NCT07206823Recruiting
Romiplostim N01 plus rituximab for ITP that didn't respond to oral TPO-RA
This trial tests a new combination of two medicines—romiplostim N01 (a shot to raise platelets) and rituximab (an infusion that calms the immune system)—for people with primary immune thrombocytopenia (ITP) who have not had enough improvement from oral TPO-RA pills like hetrombopag or eltrombopag. It aims to see if this combination works better and is safe.
Suzhou, JiangsuAges 14 years+ - NCT07195006Recruiting
Malnutrition in pregnancy and child growth study
This study looks at how nutrition during pregnancy affects the health of mothers and babies, including gut health and growth. It compares women with low nutrition to those with healthy nutrition.
HarareAges 18 years+ - NCT06680843Recruiting
Immune signatures from animal virus exposure in Cambodia
This study aims to understand how people's immune systems respond to viruses that spread from animals to humans (zoonotic viruses). If you have had recent contact with potentially infected animals in Cambodia, your participation can help researchers find ways to detect and prevent future outbreaks.
BattambangAges 18–65 - NCT06819735RecruitingPhase 1/Phase 2
Testing DT-7012 in Advanced Solid Tumors
This trial tests a new drug called DT-7012, given alone or with another immunotherapy, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if DT-7012 can shrink tumors or slow their growth.
Scottsdale, ArizonaAges 18 years+
Hear when a new Immunity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for immunity?
- Yes. Clin2 currently lists 975 recruiting immunity studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a immunity trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a immunity trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.